Skip to main content

Table 2 Prior MDS Therapies

From: Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Treated Population (N = 19)
Prior Therapies − Median (Range) 1 (0–6)
  N (%)
Chemotherapy 2 (11)
Immunotherapy 1 (5)
G-CSF 3 (16)
Investigational Agent/Drug 2 (11)
Erythropoietin 10 (53)
Steroids 3 (16)
Vitamins 2 (11)
Lenalidomide 3 (16)
  1. Abbreviations: G-CSF granulocyte colony stimulating factor.